Ultomiris Drug Market By Indication (Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, IgA Nephropathy and Other Pipeline Indications); By Patient Group (Adult Patients, Pediatric Patients); By End User (Hospitals, Specialty Clinics, Infusion Centers, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Ultomiris Drug Market: Multi-Indication C5 Inhibition, Soliris Conversion, and IgA Nephropathy Expansion Strengthen AstraZeneca’s Rare-Disease Growth Engine

The Global Ultomiris Drug Market is projected to expand from USD 4.6 billion in 2025 to USD 19.3 billion by 2032, driven by a sustained 22.7% CAGR, according to Strategic Market Research.

 

The Ultomiris Drug Market is a high-value complement-inhibition market built around ravulizumab-cwvz, AstraZeneca/Alexion’s long-acting terminal complement C5 inhibitor. Ultomiris has moved beyond its original paroxysmal nocturnal hemoglobinuria base into a broader rare-disease platform covering hematology, nephrology, and neurology. Its commercial strength comes from four factors: longer dosing interval versus Soliris, multi-indication expansion, conversion of eculizumab-treated patients, and pipeline movement into larger complement-mediated diseases such as immunoglobulin A nephropathy.

 

AstraZeneca reported Ultomiris total revenue of USD 4.718 billion in FY 2025, representing 20% year-over-year growth. The United States contributed USD 2.667 billion, Europe USD 1.053 billion, Established Rest of World USD 737 million, and Emerging Markets USD 261 million. The company attributed growth to demand across gMG, NMOSD, aHUS, and PNH, including both treatment-naïve patient uptake and ongoing conversion from Soliris. In the same financial disclosure, Soliris revenue declined 29% to USD 1.837 billion, reflecting continued migration to Ultomiris alongside competitive and biosimilar pressures in the U.S. and Europe. This positions Ultomiris as a leading example of lifecycle transition within the complement inhibitor class.

 

Long-Acting Dosing Is the Core Differentiator

Ultomiris is commercially positioned around durable C5 inhibition with less frequent infusion burden. The U.S. label lists initial U.S. approval in 2018 and approved indications for PNH, aHUS, adult AChR-antibody-positive generalized myasthenia gravis, and adult AQP4-antibody-positive neuromyelitis optica spectrum disorder. Maintenance dosing is generally every eight weeks for eligible adult patients after a loading dose, compared with Soliris’ every-two-week maintenance schedule. NICE has also noted that less frequent dosing may improve quality of life and reduce service burden.

This dosing differentiation carries commercial relevance in chronic, long-term treatment settings, where patients may remain on therapy for extended periods. Lower infusion frequency can reduce demand on infusion centers, decrease travel and caregiver burden, and improve patient tolerance of sustained treatment pathways. For payers and providers, the value proposition extends beyond clinical comparability to include improved administration efficiency in ultra-rare, high-cost, lifelong disease management.

 

PNH Remains the Original Anchor, but Competition Is Intensifying

Paroxysmal nocturnal hemoglobinuria (PNH) remains a core indication for Ultomiris. Although rare, the treated patient population generates substantial annual treatment value due to the chronic nature of complement inhibition therapy. Orphanet reports PNH incidence of about 1 in 770,000 per year and a predicted prevalence of approximately 1 in 62,500 in Great Britain. Recent real-world claims research in the U.S. reported a five-year PNH prevalence of 2.4 per 100,000 people in commercial claims, showing how diagnosed and treated prevalence can differ by data source and healthcare-access pathway.

Ultomiris established its PNH position through head-to-head evidence against eculizumab. In complement-inhibitor-naïve adults, Study 301 randomized 246 patients and showed transfusion avoidance of 73.6% with Ultomiris versus 66.1% with eculizumab, LDH normalization of 53.6% versus 49.4%, and breakthrough hemolysis of 4.0% versus 10.7%. In eculizumab-experienced patients, Study 302 showed transfusion avoidance of 87.6% with Ultomiris versus 82.7% with eculizumab and breakthrough hemolysis of 0% versus 5.1%. These outcomes supported the switch strategy from Soliris to Ultomiris without requiring patients to leave C5 inhibition.

The competitive environment in PNH has changed quickly. Novartis’ Fabhalta became the first FDA-approved oral monotherapy for adults with PNH in 2023. Apellis and Sobi’s Empaveli targets C3 and offers a proximal complement approach. Roche’s PiaSky, approved by FDA in 2024, is a C5 inhibitor with monthly subcutaneous or IV administration. Amgen’s Bkemv and Samsung Bioepis/Teva’s Epysqli are eculizumab biosimilars that pressure Soliris economics and indirectly influence payer expectations across the C5 class. AstraZeneca also added Voydeya, an oral factor D inhibitor, as add-on therapy to Ultomiris or Soliris for the subset of PNH patients with clinically significant extravascular hemolysis.

The PNH market is no longer defined solely by the Ultomiris versus Soliris comparison. It has evolved into a multi-modal competitive landscape that includes long-acting C5 inhibition, oral proximal complement inhibition, subcutaneous C5 agents, factor D add-on strategies, and emerging lower-cost eculizumab biosimilars. Ultomiris continues to benefit from an established treatment base and dosing convenience; however, treatment selection is becoming increasingly differentiated based on hemolysis profile, route of administration preference, breakthrough disease control, convenience, and cost considerations.

 

aHUS Adds Pediatric and Kidney-Focused Durability

aHUS supports Ultomiris’ nephrology base and reinforces its value in complement-mediated thrombotic microangiopathy. Epidemiology remains ultra-rare: published estimates show annual incidence ranging from 0.23 to 1.9 per million population, while Orphanet estimates European prevalence at around 1 per 100,000 and notes that aHUS accounts for 5% to 10% of hemolytic uremic syndrome cases.

The clinical data are commercially important because aHUS is associated with acute kidney injury, dialysis, and long-term renal damage. In the adult aHUS study, 56 patients were evaluated; complete TMA response occurred in 54%, platelet normalization in 84%, LDH normalization in 77%, and at least 25% serum creatinine improvement in 59%. Among patients requiring dialysis at study entry, 17 of 29 discontinued dialysis during follow-up. Pediatric aHUS data showed complete TMA response in 10 of 14 patients, or 71%, with a median response time of 30 days.

The aHUS market is smaller than gMG or potential IgAN expansion, but it is strategically important because it creates a long-duration, specialist-managed nephrology segment. It also supports pediatric use, which strengthens label breadth and formulary relevance across rare complement-mediated disorders.

 

gMG Created a Larger Neurology Opportunity but Also a More Competitive Field

Generalized myasthenia gravis expanded Ultomiris into a broader neurology market. The FDA-approved population is adult patients with AChR-antibody-positive gMG. This biomarker definition is commercially meaningful because AChR antibodies are reported in about 85% to 90% of generalized MG patients, making the addressable group much larger than PNH or aHUS.

In CHAMPION-MG, Ultomiris achieved statistically significant improvement versus placebo at Week 26. MG-ADL change was −3.1 with Ultomiris versus −1.4 with placebo, while QMG change was −2.8 versus −0.8. MG-ADL responder rate was 56.7% with Ultomiris versus 34.1% with placebo, and QMG responder rate was 30.0% versus 11.3%. These results supported Ultomiris’ move into complement-driven neuromuscular disease.

The commercial challenge is that gMG is more crowded than PNH. Argenx’s Vyvgart franchise generated USD 4.2 billion in 2025 net product sales, making it one of the strongest competitors in antibody-positive gMG and adjacent autoimmune expansion. UCB competes through Rystiggo and Zilbrysq, while AstraZeneca’s own gefurulimab, a once-weekly subcutaneous C5 inhibitor, met Phase III endpoints in gMG and could eventually create internal lifecycle pressure on infusion-based Ultomiris. Regeneron’s cemdisiran also met Phase III endpoints in gMG with every-12-week subcutaneous dosing, adding another potential competitor if approved.

Ultomiris’ gMG opportunity therefore depends on patient selection, infusion preference, payer access, neurologist familiarity with complement inhibition, and competition from FcRn blockers and subcutaneous complement programs. The class is shifting toward convenience, earlier-line use, and lower-treatment-burden formats.

 

NMOSD Strengthens High-Value Relapse-Prevention Positioning

NMOSD is a smaller market than gMG, but it carries high treatment value because relapses can produce irreversible disability. Ultomiris is approved for adult AQP4-antibody-positive NMOSD in the U.S. and EU. U.S. epidemiology research estimated that about 22,000 Americans were living with NMOSD in 2022, corresponding to prevalence of 6.9 per 100,000.

Ultomiris’ clinical result in NMOSD is one of its strongest efficacy signals. In the NMOSD study, 58 adults received Ultomiris, and no adjudicated on-trial relapses were observed during the primary treatment period. The hazard ratio versus an external placebo control was 0.014, corresponding to a 98.6% reduction in relapse risk. This creates a strong clinical case for high-risk AQP4-positive patients where relapse prevention is the central treatment objective.

The NMOSD competitive set includes Alexion’s Soliris, Horizon/Amgen’s Uplizna, and Roche/Genentech’s Enspryng. Ultomiris differentiates through longer C5-inhibitor dosing versus Soliris, but non-C5 approaches compete through different mechanisms and administration preferences. Because NMOSD is specialist-managed and relapse prevention is measurable, real-world durability and payer criteria will determine long-term uptake.

 

IgA Nephropathy Could Expand Ultomiris Beyond Ultra-Rare Markets

IgA nephropathy is the most important pipeline expansion for the Ultomiris market. AstraZeneca reported Phase III I CAN interim results in 2026 showing a 43.4% reduction in proteinuria versus placebo at 34 weeks in adults with IgAN. The FDA accepted a supplemental BLA and granted Priority Review, with a PDUFA target date anticipated in Q4 2026. AstraZeneca stated that if approved, Ultomiris would be the first C5 complement inhibitor available for IgAN.

The commercial importance is scale. AstraZeneca estimates that more than 560,000 people are diagnosed with IgAN across the U.S., EU5, and Japan, and more than 60% are eligible for IgAN treatment. That patient base is materially larger than PNH, aHUS, NMOSD, or AChR-positive gMG. A successful approval would move Ultomiris from rare-disease expansion into a broader nephrology market where proteinuria reduction, kidney-function preservation, and treatment sequencing are central commercial questions.

The IgAN market is already active. Approved or recently expanded competitors include Calliditas’ Tarpeyo/Kinpeygo, Travere’s Filspari, Novartis’ Fabhalta and Vanrafia, and other emerging kidney-disease assets. Ultomiris would enter with a terminal complement mechanism rather than an endothelin, steroid, or proximal-complement approach. Its challenge will be proving that IV C5 inhibition can justify cost and administration burden in a market where oral agents are already available and where long-term eGFR protection remains a key endpoint.

 

Safety, REMS, and Vaccination Requirements Shape Adoption

Ultomiris carries a boxed warning for serious and life-threatening meningococcal infections. The U.S. label requires meningococcal vaccination at least two weeks before the first dose unless treatment urgency outweighs delay, and Ultomiris is available only through the Ultomiris and Soliris REMS program. These requirements are manageable in specialist settings but remain commercially relevant because they affect initiation workflow, pharmacy certification, prescriber education, and patient counseling.

The risk-management requirement is especially important as Ultomiris expands into larger populations such as IgAN. In ultra-rare diseases, specialist centers are familiar with complement-inhibitor vaccination and REMS workflows. In broader nephrology use, commercial adoption would require stronger physician education, patient screening, vaccine coordination, and payer controls.

 

Pricing and Reimbursement Remain Central Commercial Filters

Ultomiris is a high-cost biologic, and payer scrutiny is intense. Canadian pharmacoeconomic materials reported submitted vial pricing and estimated annual treatment costs in adult PNH patients ranging from approximately CAD 474,284 to CAD 569,140 in subsequent treatment years, depending on weight, with higher first-year costs due to loading doses. These figures are jurisdiction-specific and should not be treated as global pricing, but they illustrate why reimbursement criteria, outcome evidence, and comparator costs matter.

In Canada, drug-assessment decisions have varied by indication and over time. Earlier CADTH materials did not recommend reimbursement for gMG, while later CDA-AMC guidance recommended reimbursement with clinical criteria and conditions for adult AChR-positive gMG. This evolution reflects the central commercial reality for Ultomiris: approval does not automatically create access. Each indication must pass clinical, economic, and payer-control tests.

 

Regional Market Outlook

North America is the largest commercial region for Ultomiris. AstraZeneca reported USD 2.667 billion in U.S. Ultomiris revenue in FY 2025, representing more than half of global reported Ultomiris revenue. U.S. growth is supported by multi-indication approval, strong rare-disease diagnosis infrastructure, neurologist and nephrologist adoption, specialty-pharmacy capability, and high biologic reimbursement capacity. U.S. Priority Review in IgAN makes the region the most important near-term catalyst market.

Europe generated USD 1.053 billion in FY 2025 Ultomiris revenue, with AstraZeneca reporting strong demand growth after recent launches but also competition in gMG and PNH. Europe is commercially attractive but cost-effectiveness controlled. NICE, national HTA bodies, and country-level reimbursement agencies influence uptake, especially where C5 inhibitor costs are compared with Soliris, eculizumab biosimilars, or non-C5 alternatives.

Established Rest of World generated USD 737 million in FY 2025 and remains important because Japan has been an early and active complement-inhibitor market across PNH, aHUS, and NMOSD. Emerging Markets generated USD 261 million but grew 84% year over year, making geographic expansion a visible growth lever. Emerging-market growth will depend on diagnosis rates, tender systems, ability to fund ultra-rare biologics, and physician access to complement-specialist care.

 

Competitive Landscape

AstraZeneca/Alexion remains the central company in the Ultomiris market, with Soliris, Ultomiris, and Voydeya forming a complement-inhibition franchise. Xencor remains financially linked through Ultomiris royalty economics tied to its antibody-engineering technology, and OMERS acquired certain global Ultomiris royalty rights from Xencor beginning in 2023.

In PNH, key competitors include Novartis with Fabhalta, Apellis and Sobi with Empaveli, Roche/Genentech with PiaSky, Amgen with Bkemv, and Samsung Bioepis/Teva with Epysqli. In gMG, Argenx’s Vyvgart franchise, UCB’s Rystiggo and Zilbrysq, Regeneron’s cemdisiran program, and AstraZeneca’s own gefurulimab represent major competitive pressure. In NMOSD, Soliris, Uplizna, and Enspryng compete for AQP4-positive relapse prevention. In IgAN, Ultomiris would compete against a rapidly expanding nephrology field led by Tarpeyo/Kinpeygo, Filspari, Fabhalta, Vanrafia, and other agents targeting proteinuria and kidney-function preservation.

 

Analyst Insight

The Ultomiris Drug Market is no longer defined by a single-indication paroxysmal nocturnal hemoglobinuria conversion narrative. It has evolved into a multi-indication complement inhibition platform supported by an established revenue base and multiple competitive inflection points. PNH and atypical hemolytic uremic syndrome provide durable rare-disease treatment continuity, while generalized myasthenia gravis and neuromyelitis optica spectrum disorder expand the neurology footprint but introduce exposure to faster-moving competitive dynamics. IgA nephropathy represents a potential major future opportunity pending regulatory approval, although it is also likely to attract greater payer scrutiny and increased competition from emerging oral nephrology therapies.

The central commercial consideration is whether Ultomiris can maintain its long-acting C5 inhibition advantage as the complement market evolves toward oral therapies, subcutaneous formulations, biosimilars, add-on regimens, and indication-specific mechanisms. FY 2025 revenue growth indicates continued conversion from Soliris alongside sustained demand from new indications. Future growth will depend on three key factors: maintaining access across established rare-disease indications, defending against convenience-driven competition, and demonstrating a differentiated clinical role for terminal C5 inhibition in IgA nephropathy.

 

Ultomiris Drug Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 4.6 Billion
Revenue Forecast in 2032	USD 19.3 Billion
Overall Growth Rate	CAGR of 22.7% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion and CAGR (2026–2032)
Segmentation	By Indication, By Patient Group, By End User, By Geography
By Indication	Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic Syndrome; Generalized Myasthenia Gravis; Neuromyelitis Optica Spectrum Disorder; IgA Nephropathy; Other Pipeline Indications
By Patient Group	Adult Patients; Pediatric Patients
By End User	Hospitals; Specialty Clinics; Infusion Centers; Academic and Research Institutions
By Region	North America; Europe; Asia-Pacific; Latin America; Middle East and Africa
Country Scope	United States; Canada; United Kingdom; Germany; France; Italy; Spain; Japan; China; South Korea; Australia; Brazil; Mexico; Saudi Arabia; United Arab Emirates; South Africa
Market Drivers	Longer maintenance-dosing interval compared with Soliris; Continued conversion of eligible Soliris-treated patients to Ultomiris; Expansion across hematology, nephrology, and neurology indications; Potential entry into the larger IgA nephropathy population
Customization Option	Available upon request